EirGenix, a contract development and manufacturing organization (CDMO) and a biosimilars maker, has opened a new protein production facility at the Hsinchu Biomedical Park in Zubei, Taiwan, boosting its CDMO capabilities. 
 
In addition to the new facility, the company, together with its parent, Formosa Labs, signed an agreement with Spain’s Oncomatryx Biopharma for the development of new antibody drug conjugates (ADCs). 
 
Since its formation in December 2012, EirGenix has completed more than 10 CDMO projects for overseas customers. It also operates a subsidiary, Formosa Pharmaceuticals, which offers new drug development services. It is currently building an injectable manufacturing plant with the goal of being a one-stop-shop from API manufacturing to drug product filling.